ArticleThe New England journal of medicine2014
HDL cholesterol efflux capacity and incident cardiovascular events.
Article in The New England journal of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 726 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
726 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,369 citations in OpenAlex.
- Estimating the burden of adult diabetes in China: a systematic review and meta-analysis with attributable risk assessment.BMC public health · 2025Pooled it
- High-density lipoprotein particles are associated with the risk of mortality from all-causes and cardiovascular diseases (CVDs) in patients with CVD: a systematic review and meta-analysis study.Lipids in health and disease · 2025Pooled it
- Impact of a Chokeberry (Nutrients · 2025Pooled it
- Association between the High-density Lipoprotein Cholesterol Efflux Capacity and the Long-term Prognosis in Patients with Coronary Artery Disease: A Meta-analysis.Journal of atherosclerosis and thrombosis · 2025Pooled it
- Effects of exercise combined with different dietary interventions on cardiovascular health a systematic review and network meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- Trial
- Lomitapide modifies high-density lipoprotein function in homozygous familial hypercholesterolaemia.European journal of medical research · 2025Trial
- The Role of Exercise-Based Cardiac Rehabilitation After Myocardial Infarction on Cholesterol Transfer to HDL.International journal of molecular sciences · 2025Trial
- Effects of dietary interventions and intermittent fasting on HDL function in obese individuals with T2DM: a randomized controlled trial.Cardiovascular diabetology · 2024Trial
- Extra virgin olive oil improves HDL lipid fraction but not HDL-mediated cholesterol efflux capacity: a double-blind, randomised, controlled, cross-over study (OLIVAUS).The British journal of nutrition · 2023Trial
- Trial
- Very low HDL cholesterol in infectious mononucleosis with hepatitis: a real-world evidence study.Atherosclerosis plus · 2026Article
- Altered global longitudinal strain is a common finding in liver transplant recipients with mild cardiometabolic burden.Internal and emergency medicine · 2026Observational
- Intraperitoneal Isoastragaloside II Attenuated Western Diet-Induced Atherosclerosis in Male ApoENutrients · 2026Article
- GLP-1 Receptor Agonists as Molecular Relievers of Lipotoxic Stress: From Pancreatic Beta-Cell Cholesterol Efflux to Systemic and Tissue-Specific Metabolic Protection.International journal of molecular sciences · 2026Review
- Regulatory Bottlenecks Linking HDL Dysfunction, Inflammation, and Oxidative Stress: A Petri Net-Based Systems Analysis.International journal of molecular sciences · 2026Article
- Key Hepatokines Linking MASLD and Type 2 Diabetes: From Pathophysiological Mechanisms to Therapeutic Modulation.International journal of molecular sciences · 2026Review
- Profiling Cardiovascular Disease-Associated Changes in the Composition of High-Density Lipoprotein Particles.Cardiovascular drugs and therapy · 2026Review
- Early atherogenesis: In search of etiology.International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- Mesoporous Silica-Confined Ruthenium Nanozyme Motors Reprogram Redox-Inflammatory Crosstalk to Suppress Atherosclerosis via NRF2 Nuclear Translocation.Advanced healthcare materials · 2026Article
666 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundIt is unclear whether high-density lipoprotein (HDL) cholesterol concentration plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux capacity, the ability of HDL to accept cholesterol from macrophages, which is a key step in reverse cholesterol transport. We investigated the epidemiology of cholesterol efflux capacity and its association with incident atherosclerotic cardiovascular disease outcomes in a large, multiethnic population cohort.
methodsWe measured HDL cholesterol level, HDL particle concentration, and cholesterol efflux capacity at baseline in 2924 adults free from cardiovascular disease who were participants in the Dallas Heart Study, a probability-based population sample. The primary end point was atherosclerotic cardiovascular disease, defined as a first nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization or death from cardiovascular causes. The median follow-up period was 9.4 years.
resultsIn contrast to HDL cholesterol level, which was associated with multiple traditional risk factors and metabolic variables, cholesterol efflux capacity had minimal association with these factors. Baseline HDL cholesterol level was not associated with cardiovascular events in an adjusted analysis (hazard ratio, 1.08; 95% confidence interval [CI], 0.59 to 1.99). In a fully adjusted model that included traditional risk factors, HDL cholesterol level, and HDL particle concentration, there was a 67% reduction in cardiovascular risk in the highest quartile of cholesterol efflux capacity versus the lowest quartile (hazard ratio, 0.33; 95% CI, 0.19 to 0.55). Adding cholesterol efflux capacity to traditional risk factors was associated with improvement in discrimination and reclassification indexes.
conclusionsCholesterol efflux capacity, a new biomarker that characterizes a key step in reverse cholesterol transport, was inversely associated with the incidence of cardiovascular events in a population-based cohort. (Funded by the Donald W. Reynolds Foundation and others.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.